There is a sanity clause by Petsko, Gregory A
Last month I tried to inject some sanity into the debate 
about  the  establishment  of  a  new  National  Center  for 
Advancing  Translational  Sciences  (NCATS)  at  the 
National Institutes of Health (NIH). NCATS, the favored 
child of NIH Director Francis Collins, has as its stated 
scientific  rationale:  “to  develop  and  offer  innovative 
services  and  expertise  in  moving  promising  products 
through  the  development  pipeline,  as  well  as  develop 
novel approaches to therapeutics development, stimulate 
new avenues for basic scientific discovery, and comple­
ment the strengths of existing NIH research activities”. 
My argument, you may recall, was that it was right to 
worry  about  this  new  initiative  to  facilitate  curing 
diseases being oversold to Congress and the US public, 
just  as  the  War  on  Cancer  and  the  Human  Genome 
Project and the NIH budget doubling and the Structural 
Genomics Initiative and the Cancer Genomics program 
and  genome­wide  association  studies  have  been.  I 
pointed out that curing disease is difficult, time­consum­
ing,  and  usually  depends  on  breakthroughs  that  were 
never part of any targeted research program. I stressed 
the  importance  of  funding  individual  investigator­
initiated, curiosity­driven projects as the essential plat­
form  on  which  all  so­called  ‘translational  research’  ­ 
research  aimed  at  translating  basic  discoveries  into 
disease cures and prevention ­ must be built.
But ­ and to the surprise of some of you from the res­
ponse I got ­ I also said that I didn’t think the forma  tion 
of NCATS was necessarily a bad idea, and I promised to 
explain why and to offer some concrete suggestions for 
how it might turn into a good idea. Before I do that, I 
should point out that some of the flap over its creation 
has to do not with the idea of NCATS itself but with the 
fate  of  another  NIH  Center,  the  National  Center  for 
Research  Resources  (NCRR)  ­  and  yes,  I  know,  this 
column  really  ought  to  be  an  acronym­free  zone,  but 
we’re  dealing  with  the  Federal  Government  here,  and 
YJBGUTI (You Just Better Get Used To It).
The total number of NIH Institutes and Centers is fixed 
by  a  2006  federal  law  at  27,  which  is  what  there  are 
currently, so if one is to be added, something has to go. 
Collins  decided  last  year  to  combine  the  National 
Institute on Drug Abuse and the National Institute on 
Alcohol  Abuse  and  Alcoholism  into  a  new  Addictions 
institute, which would free up a slot, but that merger is 
on a long time line and, as I explained last month, Collins 
is in a hurry to get NCATS started. So he has proposed 
eliminating NCRR and, in addition to vast anxieties on 
the part of the people who work there, this decision has 
created a stir among research scientists who depend on 
the  resources  that  NCRR  provides,  and  among  NIH 
supporters in Congress, some of whom are starting to 
feel that the elimination of that Center and the establish­
ment of a new one is being done without due deliberation 
and consultation.
At the moment, NCRR supports all aspects of clinical 
and  translational  research,  including  the  Clinical  and 
Translational  Science  Awards,  by  which  the  Center 
identifies innovative research teams and equips them with 
essential  tools  and  critical  resources  needed  to  tackle 
complex  health  problems.  In  addition,  it  estab  lishes 
clinical  research  infrastructure,  including  special  ized 
research staff, informatics support, and laboratories that 
enable  studies  of  the  full  range  of  human  disorders;  it 
funds career development programs for medical students 
and  physicians;  and  it  funds  development  programs  for 
underserved states and institutions that focus on health 
disparities  that  affect  racial  and  ethnic  minority  popu­
lations.  It  also  provides  access  to  state­of­the  art  tech­
nologies  and  instruments  that  enable  both  basic  bio­
medical research and clinical investigations of a multi  tude 
of health issues, from cancer to infectious diseases, and 
develops and provides access to critical animal models for 
a  broad  range  of  human  disorders,  such  as  Parkinson’s 
disease, multiple sclerosis, and AIDS. It’s also one of the 
few  places  that  institutions  can  go  to  for  funding  to 
expand, remodel, and renovate or alter exist  ing research 
facilities  or  construct  new  research  facilities.  In  short, 
NCRR does quite a lot of things that are directly connected 
to translating discoveries into cures, but it’s not clear that 
these programs are going to be subsumed into NCATS or 
that they will find homes at other Institutes and Centers 
where they will not become poor stepchildren. And this 
uncertainty is getting a number of people upset.
So  the  whole  thing  could  conceivably  get  killed 
before it gets started, but I don’t think that’s going to  © 2010 BioMed Central Ltd
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reality,  because  Collins  has  staked  his  prestige  and 
legacy on its creation and there are lots of people out 
there who feel the NIH needs to do more to foster the 
development of therapies.
Besides, as I alluded to above, I don’t think NCATS is a 
terrible idea per se. The devil, as always, is in the details, 
and up to now the details have been rather lacking. Which 
is perfect, because where there is a vacuum of infor  mation, 
pundits  such  as  I  can  rush  in  with  un  solicited  advice. 
Which, again in the spirit of being sane and sober about 
this whole business, is what I’m now finally about to do.
If I had to summarize the non­NCRR­related objections 
to the new Center in a single sentence, it would be that 
the NIH has no business doing what pharmaceutical and 
biotechnology companies are supposed to do, and would 
probably do better. Of course, it could always be argued 
that there are many diseases that the private sector isn’t 
interested  in  because  the  market  is  too  small  or  the 
challenge is too difficult, and NCATS could simply focus 
on these ­ and that is one of the arguments that in fact is 
being  made  for  its  establishment.  But  I  don’t  buy  that 
rationale. Making drugs, especially small­molecule drugs, 
is no job for amateurs, and that’s exactly what NIH is 
when it comes to the pharmaceutical business.
The time­line for small­molecule drug development is 
extremely long and the success rate is extremely low. It’s 
also more of an art than a science. In every drug company 
there  are  literally  hundreds  of  chemists,  but  only  a 
handful of them will have ever really made a drug, and 
only these same handful ever will make another one ­ all 
of the rest are simply supporting the efforts of the ones 
who have the knack. If NCATS tries to get into the drug­
making  business  without  a  number  of  these  especially 
talented chemists, the odds are they will never make one.
But this consideration does not apply to biopharma  ceu­
ticals such as protein drugs. Antibodies and hormones and 
other ‘biologicals’, as the drugs industry calls them, are 
preselected  for  efficacy  by  natural  selection,  and 
consequently have a much shorter time­line to the clinic 
and a lower failure rate in clinical trials than chemical 
drugs. True, after leaving this arena to the biotechnology 
companies  for  decades,  the  large  pharmaceutical 
companies are now playing in it with a vengeance, but 
there is still plenty of room for an outsider to play in the 
smaller arena of rare disorders. So my first suggestion is 
that, if NCATS is going to try to develop drugs on its 
own, they need to be macromolecular drugs.
But I think an even better strategy would be for NCATS 
to focus, not on discovering its own pharmaceuticals, but 
on  finding  ways  to  overcome  the  roadblocks  that  are 
preventing  private  industry  from  doing  that  more  effi­
ciently.  For  example,  delivery  of  biopharmaceuticals  is 
often difficult, expensive, and discomforting for the patient. 
Better delivery strategies would be welcome. In addition, 
nearly all biologicals, even those that are supposedly pure 
human proteins, are immunogenic to some (and some­
times  many)  patients.  The  reason  is  not  impurities  so 
much  as  the  presence,  in  chemically  pure  samples,  of 
mis  folded and aggregated material, which break immune 
tolerance. New methods to produce biopharmaceuticals 
and to purify and store them while retaining confor  ma­
tional homogeneity would be a huge advance for the field.
Other bottlenecks are similarly easy to identify. A large 
percentage of drugs fail in Phase II clinical trials because 
they are not efficacious against the disease for which they 
were intended. Yet they obviously seemed to be effective 
in preclinical studies, and were deemed safe in people in 
Phase  I  studies.  All  of  which  suggests  to  me  that  our 
animal  models  for  toxicity  are  pretty  good,  but  our 
models for disease are not. The development of cellular 
and  animal  disease  models  that  would  allow  more 
accurate, and earlier, target validation would enormously 
accelerate the translation of basic research into the clinic.
I could list several more (for example: Why do so many 
drugs  produce  peripheral  neuropathy,  and  is  there  any 
way to either predict this in advance or to get around it? 
Another  common  side­effect  of  many  drugs  is  cardiac 
arrythmia;  why  is  that  so,  and  what  are  the  off­target 
macromolecules responsible for it? Can Phase II failures, 
which after all have been shown to be safe in people, be 
resurrected,  Lazarus­style,  for  other  diseases  that  were 
not their target in the first place? and so on), but you get 
the idea. If NCATS did nothing more but gather all the 
failed drugs from all the clinical trials conducted by all the 
pharmaceutical and biotechnology companies and make 
them available to researchers in universities and medical 
schools in the US and elsewhere, I would bet it would find 
several useful ‘new’ drugs in a matter of a few years. And 
as for my other ideas, well, the way to work on those is not 
for NCATS to do its own in­house research or to fund big 
drug  development  projects  in  big  centers  in  big 
institutions; these are fundamental questions that need to 
be  answered  and  the  way  to  do  that  is  with  individual 
investigator­initiated grants. Lots of them. NCATS should 
pose the questions (or call them ‘grand challenges’ if you 
prefer),  evaluate  the  proposals  that  come  in  to  answer 
them, fund the best, and then get out of the way.
In other words, the best strategy for NCATS to make a 
real difference in translational research is, ironically, for it 
to fund a lot of basic research. I know that sounds crazy, 
but then, there’s a fine line between genius and insanity, 
and maybe it’s time we erased it.
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